Drug Trial Radar · NCT06710925
A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Nov 28, 2024
Primary completion
Jul 27, 2025
Study completion Dec 14, 2025
Sponsor
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 weeks, up to 12 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and immunogenicity of TNM001 in high-risk infants when entering their RSV season. Approximately 201 infants will be randomized in a ratio of 2:1 to receive TNM001 or placebo. All subjects will be followed for 270 days after dosing. This study will be conducted at approximately 20 sites in China.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
TNM001Biological
single dose intramuscular injection
placeboBiological
single dose intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of medically attended LRTI due to RT-PCR confirmed RSVTime frame: 150 days post dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Children's Hospital of Chongqing Medical University
Chongqing, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.